Kanabo appointed to BSI Steering Group Committee

RNS Number : 7908D

Kanabo Group PLC

24 October 2022

 

RNS Reach

Kanabo Group Plc

("Kanabo" or the "Company")

Kanabo appointed to BSI Steering Group Committee

A New British Standard: Kanabo Group Kanabo Group has been invited to co-develop standard specifications for the safety, quality and performance of CBD vape products to ensure consistency of quality and consumer protection.

Kanabo Group plc (LSE:KNB) the pan-European medical cannabis company that focuses on developing and commercialising cannabis-derived products for medical patients and wellness consumers, has been selected as a steering group member for the development of a British Standard for CBD non-tobacco Vape products.

CBD Vape products provide an alternative method to consuming CBD, which has been dominated by food and cosmetic products. Standardisation of the category is currently minimal and has historically focused on the safety of electronic components of CBD Vape products. The British Standards Institution ("BSI") has announced a Publicly Available Specifications ("PAS") expected to be published in early 2023 for CBD Vape Products to develop a standard specification for their safety, quality, and performance, which will ensure consumer protection while driving category growth.

PAS is a sponsored standardisation document compiled and co-developed by industry experts and stakeholders, defining best practice with the goal of introducing standardisation. The PAS is authored by a steering group representing an equitable spread of stakeholder expertise and opinion. Kanabo Group's appointment to the steering committee of PAS 13956 will leverage the pioneering experience, research and development of the CBD and cannabis specialist - including extensive clinical and validation activities, as well as safety and efficiency tests conducted by the Group.

Headquartered in the UK with research and development facilities centred in Israel (an established leader in the cannabis industry) the Pan-European Kanabo Group is focused on developing and commercialising cannabis-derived products for medical patients and wellness CBD consumers. This includes the unique development of high-quality cannabis extract formulas and innovating medical-grade vaporisers and non-combustible inhalation consumption solutions with pharmaceutical grade production standards to produce the highest quality high potency and vegan friendly CBD vape products for consumers. Kanabo Group's experience and expertise will inform the BSI document to provide a standard specification for the safety, quality, and performance of CBD Vape products in order to ensure consumer protection under reasonable and foreseeable conditions based on Kanabo's own self-regulated standards that include comprehensive safety data, pharmaceutical grade manufacturing practices and stringent product purity testing to ensure no dilutants are used.

Avihu Tamir, CEO Kanabo Group Plc, said: "We are delighted to be included within this PAS steering group. We have always taken a safety-first approach to our CDB products and delivery devices, which includes educating consumers about our products and their quality. We always undertake stringent safety and efficacy studies as part of our product development programmes and are unique in the industry in making these results available to the public. These important developments will provide consumers with confidence and ultimately shape the CBD Vape industry.

"Kanabo Group has plans to reach out to the UK Government's Medicines and Healthcare products Regulatory Agency to highlight the PAS publication and share their standards for testing the safety and efficacy of new products in the hope that the same exacting process and consumer transparency will inform the assessment and establishment of national standards."

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Kanabo Group Plc	Via Vox Markets
Investor Enquiries Kat Perez / Richard Fabris	[e-mail]
Media Enquiries Nic Barnes	[e-mail]

About Kanabo Group Plc

Kanabo Group Plc is a leading developer and distributer of cannabis-derived products and inhalation technologies for medical patients and non-THC products for CBD consumers. Kanabo Group Plc was the first medicinal cannabis company to IPO on London Stock Exchange and is made up of supply-chain specialist subsidiaries, from cultivation consultancy to R&D to formula development and distribution, including:

· Kanabo Agritec Ltd, a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

· Kanabo Research Ltd, a wholly owned subsidiary of Kanabo Group Plc, responsible for R&D, regulation, and quality assurance procedures.

· The GP Service - a Kanabo Group Plc owned, NHS approved online telehealth provider offering video consultations, online prescriptions, treatment forms and access to both Kanabo medical-cannabis and wellbeing CBD products .

 

END

 

 

NRAFLFVDISLVFIF